Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store

Evofem Biosciences, Inc. has expanded its "Say Vagina" campaign with the launch of the Say Vagina Store, aimed at normalizing discussions around female anatomy and promoting education in women's health. The campaign seeks to combat the censorship of proper anatomical terminology across digital platforms, where educational discussions are often shadow-banned due to algorithmic biases that equate clinical language with explicit content. According to Evofem’s CEO Saundra Pelletier, this initiative is about transforming societal stigma into empowerment through the normalization of language.

Originally initiated in August 2025, the "Say Vagina" campaign emphasizes the importance of accurate, uncensored health communication, thereby enhancing public understanding of women's health. The newly launched Say Vagina Store serves as a platform to promote dialogue, awareness, and cultural change in this space. Evofem's broader philosophy prioritizes transparency, education, and respect in women’s healthcare, which influences its approach to innovation and patient care.

The campaign is gaining national attention and will further its outreach with a featured panel at SXSW 2026, discussing the implications of digital censorship on women's health education and outcomes. Pelletier articulates the need for women to have their voices heard: “More than half the population has a vagina, but its proper anatomical name remains heavily censored and stigmatized.” The Say Vagina Store can be visited at www.SayVaginaStore.com, reinforcing the campaign's objective to encourage open dialogue about women’s health and reclaim the narrative around female anatomy.

Evofem Biosciences is also known for its FDA-approved products, PHEXX® and SOLOSEC®, which cater to sexual and reproductive health needs.

Evofem Biosciences, Inc. (OTC: EVFM) recently launched the "Say Vagina Store," an innovative extension of its ongoing "Say Vagina" campaign, which seeks to normalize women’s health language. This initiative represents a significant effort to combat the stigma and digital censorship surrounding proper anatomical terminology. The success of this campaign could have a positive impact on the company's brand recognition and product sales, especially for its unique offerings: PHEXX® and SOLOSEC®.

From a market perspective, the launch highlights Evofem's commitment to addressing a critical gap in women's healthcare discourse. By fostering an environment where open conversations about women's health are encouraged, Evofem positions itself as a leader in a niche but growing market. The implications of this pivot are twofold: an increased visibility of the issues surrounding women's health may lead to a higher demand for educational resources and related products, ultimately benefiting Evofem’s bottom line.

As Evofem gears up for broader visibility at platforms like SXSW in 2026, investors should closely monitor developments surrounding this campaign and its engagement strategies. Increased awareness and advocacy can lead not just to improved health outcomes but also to potential partnerships, expanded distribution channels, and enhanced sales.

Moreover, the company's focus on educational initiatives indicates a proactive approach toward regulatory challenges and market entry barriers often faced by women’s health products. With a market increasingly valuing transparency and authentic engagement, Evofem is likely to benefit from its efforts to foster community dialogue and advocate for women’s health rights.

In summary, Evofem's strategic expansion into the educational and advocacy space with the "Say Vagina Store" presents a compelling case for investors looking for opportunities in the evolving landscape of women’s health. Keeping track of campaign visibility and consumer engagement could be key indicators of the company's future performance.